Lipocine (LPCN) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lipocine (LPCN) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 38.9% versus a loss of 97.3%. Over five years, LPCN leads with a -90.0% price change compared with -99.8% for TVRD. Lipocine is the larger company by market cap ($14.3 million vs $13.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | TVRD |
|---|---|---|
| Share price | $1.74 | $1.04 |
| Market cap | $14.35M | $13.81M |
| 1-day change | -9.84% | -4.17% |
| YTD return | -75.97% | -74.88% |
| 1-year return | -38.92% | -97.29% |
| 5-year return | -89.95% | -99.77% |
| EPS (TTM) | $-1.85 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.37 | $43.65 |
| 52-week low | $1.73 | $0.93 |
| Distance from 52-week high | -85.93% | -97.63% |
| Analyst consensus | none | buy |
| Avg. price target upside | +187.34% | +793.72% |
| Average volume | 1.72M | 424.45K |
| Shares outstanding | 8.24M | 13.34M |
| Employees | 14 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed TVRD by 58.4 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
LPCN vs TVRD FAQ
Which is bigger, Lipocine or Tvardi Therapeutics?
Lipocine (LPCN) is larger, with a market capitalization of $14.35M compared with $13.81M for Tvardi Therapeutics (TVRD).
Which stock has performed better over the past year, LPCN or TVRD?
LPCN returned -38.92% over the past 12 months, compared with -97.29% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.